Trials / Recruiting
RecruitingNCT06380361
InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sensome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.
Detailed description
Participants in this study require a lung biopsy to confirm if they have a lung tumour. A biopsy is a procedure where a piece of lung tissue is removed for testing. Current biopsy techniques cannot guarantee the exact location of lung tumours, so biopsies can be taken from healthy tissue. The BioSpy System (BSS) is a device with a probe, which is placed inside a normal biopsy needle. The tip of the probe contains sensors, that will scan the composition of the tissue which is in contact with the sensors. The INSPECT study aims at collecting the sensor data, with the goal of being able to differentiate the different tissues. All study participants will have a biopsy with the BSS. Participants will have a hospital visit for the procedure, and will have to stay up to 16 hours after their procedure as per normal hospital practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | BioSpy System | One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure. |
Timeline
- Start date
- 2024-03-28
- Primary completion
- 2025-03-31
- Completion
- 2025-04-01
- First posted
- 2024-04-23
- Last updated
- 2025-01-13
Locations
2 sites across 2 countries: Australia, France
Source: ClinicalTrials.gov record NCT06380361. Inclusion in this directory is not an endorsement.